2020EAN大会速递丨青少年NMOSD患者Satralizumab给药方案:与成年患者一致

2020-06-10 MedSci原创 MedSci原创

青少年NMOSD患者Satralizumab给药方案:与成年患者一致

青少年NMOSD患者Satralizumab给药方案:与成年患者一致

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1678192, encodeId=338716e819223, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 24 13:26:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674270, encodeId=001016e4270e8, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15914, encryptionId=589615914ee, topicName=Satralizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ef626951425, createdName=zblhy, createdTime=Fri Mar 26 00:26:32 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912378, encodeId=75c719123e817, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 31 14:26:32 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657328, encodeId=db78165e328ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 03 23:26:32 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947495, encodeId=790a194e49580, content=<a href='/topic/show?id=c11f29e67e' target=_blank style='color:#2F92EE;'>#ATRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2976, encryptionId=c11f29e67e, topicName=ATRA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Aug 02 11:26:32 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805811, encodeId=b73718058111e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78858, encryptionId=e976e885830, topicName=给药方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 24 23:26:32 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539036, encodeId=3441153903650, content=<a href='/topic/show?id=de5d1288950' target=_blank style='color:#2F92EE;'>#NMOSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12889, encryptionId=de5d1288950, topicName=NMOSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1f13099713, createdName=AspirantSuo, createdTime=Fri Jun 12 02:26:32 CST 2020, time=2020-06-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1678192, encodeId=338716e819223, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 24 13:26:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674270, encodeId=001016e4270e8, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15914, encryptionId=589615914ee, topicName=Satralizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ef626951425, createdName=zblhy, createdTime=Fri Mar 26 00:26:32 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912378, encodeId=75c719123e817, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 31 14:26:32 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657328, encodeId=db78165e328ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 03 23:26:32 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947495, encodeId=790a194e49580, content=<a href='/topic/show?id=c11f29e67e' target=_blank style='color:#2F92EE;'>#ATRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2976, encryptionId=c11f29e67e, topicName=ATRA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Aug 02 11:26:32 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805811, encodeId=b73718058111e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78858, encryptionId=e976e885830, topicName=给药方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 24 23:26:32 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539036, encodeId=3441153903650, content=<a href='/topic/show?id=de5d1288950' target=_blank style='color:#2F92EE;'>#NMOSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12889, encryptionId=de5d1288950, topicName=NMOSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1f13099713, createdName=AspirantSuo, createdTime=Fri Jun 12 02:26:32 CST 2020, time=2020-06-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1678192, encodeId=338716e819223, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 24 13:26:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674270, encodeId=001016e4270e8, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15914, encryptionId=589615914ee, topicName=Satralizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ef626951425, createdName=zblhy, createdTime=Fri Mar 26 00:26:32 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912378, encodeId=75c719123e817, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 31 14:26:32 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657328, encodeId=db78165e328ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 03 23:26:32 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947495, encodeId=790a194e49580, content=<a href='/topic/show?id=c11f29e67e' target=_blank style='color:#2F92EE;'>#ATRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2976, encryptionId=c11f29e67e, topicName=ATRA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Aug 02 11:26:32 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805811, encodeId=b73718058111e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78858, encryptionId=e976e885830, topicName=给药方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 24 23:26:32 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539036, encodeId=3441153903650, content=<a href='/topic/show?id=de5d1288950' target=_blank style='color:#2F92EE;'>#NMOSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12889, encryptionId=de5d1288950, topicName=NMOSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1f13099713, createdName=AspirantSuo, createdTime=Fri Jun 12 02:26:32 CST 2020, time=2020-06-12, status=1, ipAttribution=)]
    2020-10-31 snf701207
  4. [GetPortalCommentsPageByObjectIdResponse(id=1678192, encodeId=338716e819223, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 24 13:26:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674270, encodeId=001016e4270e8, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15914, encryptionId=589615914ee, topicName=Satralizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ef626951425, createdName=zblhy, createdTime=Fri Mar 26 00:26:32 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912378, encodeId=75c719123e817, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 31 14:26:32 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657328, encodeId=db78165e328ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 03 23:26:32 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947495, encodeId=790a194e49580, content=<a href='/topic/show?id=c11f29e67e' target=_blank style='color:#2F92EE;'>#ATRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2976, encryptionId=c11f29e67e, topicName=ATRA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Aug 02 11:26:32 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805811, encodeId=b73718058111e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78858, encryptionId=e976e885830, topicName=给药方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 24 23:26:32 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539036, encodeId=3441153903650, content=<a href='/topic/show?id=de5d1288950' target=_blank style='color:#2F92EE;'>#NMOSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12889, encryptionId=de5d1288950, topicName=NMOSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1f13099713, createdName=AspirantSuo, createdTime=Fri Jun 12 02:26:32 CST 2020, time=2020-06-12, status=1, ipAttribution=)]
    2020-11-03 bsmagic9140
  5. [GetPortalCommentsPageByObjectIdResponse(id=1678192, encodeId=338716e819223, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 24 13:26:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674270, encodeId=001016e4270e8, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15914, encryptionId=589615914ee, topicName=Satralizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ef626951425, createdName=zblhy, createdTime=Fri Mar 26 00:26:32 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912378, encodeId=75c719123e817, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 31 14:26:32 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657328, encodeId=db78165e328ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 03 23:26:32 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947495, encodeId=790a194e49580, content=<a href='/topic/show?id=c11f29e67e' target=_blank style='color:#2F92EE;'>#ATRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2976, encryptionId=c11f29e67e, topicName=ATRA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Aug 02 11:26:32 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805811, encodeId=b73718058111e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78858, encryptionId=e976e885830, topicName=给药方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 24 23:26:32 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539036, encodeId=3441153903650, content=<a href='/topic/show?id=de5d1288950' target=_blank style='color:#2F92EE;'>#NMOSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12889, encryptionId=de5d1288950, topicName=NMOSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1f13099713, createdName=AspirantSuo, createdTime=Fri Jun 12 02:26:32 CST 2020, time=2020-06-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1678192, encodeId=338716e819223, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 24 13:26:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674270, encodeId=001016e4270e8, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15914, encryptionId=589615914ee, topicName=Satralizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ef626951425, createdName=zblhy, createdTime=Fri Mar 26 00:26:32 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912378, encodeId=75c719123e817, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 31 14:26:32 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657328, encodeId=db78165e328ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 03 23:26:32 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947495, encodeId=790a194e49580, content=<a href='/topic/show?id=c11f29e67e' target=_blank style='color:#2F92EE;'>#ATRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2976, encryptionId=c11f29e67e, topicName=ATRA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Aug 02 11:26:32 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805811, encodeId=b73718058111e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78858, encryptionId=e976e885830, topicName=给药方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 24 23:26:32 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539036, encodeId=3441153903650, content=<a href='/topic/show?id=de5d1288950' target=_blank style='color:#2F92EE;'>#NMOSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12889, encryptionId=de5d1288950, topicName=NMOSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1f13099713, createdName=AspirantSuo, createdTime=Fri Jun 12 02:26:32 CST 2020, time=2020-06-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1678192, encodeId=338716e819223, content=<a href='/topic/show?id=7f2c1e736f1' target=_blank style='color:#2F92EE;'>#TRALI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17736, encryptionId=7f2c1e736f1, topicName=TRALI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jul 24 13:26:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674270, encodeId=001016e4270e8, content=<a href='/topic/show?id=589615914ee' target=_blank style='color:#2F92EE;'>#Satralizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15914, encryptionId=589615914ee, topicName=Satralizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ef626951425, createdName=zblhy, createdTime=Fri Mar 26 00:26:32 CST 2021, time=2021-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912378, encodeId=75c719123e817, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Oct 31 14:26:32 CST 2020, time=2020-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1657328, encodeId=db78165e328ef, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Tue Nov 03 23:26:32 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947495, encodeId=790a194e49580, content=<a href='/topic/show?id=c11f29e67e' target=_blank style='color:#2F92EE;'>#ATRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2976, encryptionId=c11f29e67e, topicName=ATRA)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/XhttJCp4Aq9gKA5n4v9elclQlVQTDenMiaEiadlI5D3gtmfSiaicoIY4ZsuibrQKLibDdxBKVY8oS6B2FicqJlT93clow/132, createdBy=03202500144, createdName=ms7258648636991762, createdTime=Sun Aug 02 11:26:32 CST 2020, time=2020-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1805811, encodeId=b73718058111e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78858, encryptionId=e976e885830, topicName=给药方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b632500090, createdName=h.y200607_23674418, createdTime=Sat Oct 24 23:26:32 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539036, encodeId=3441153903650, content=<a href='/topic/show?id=de5d1288950' target=_blank style='color:#2F92EE;'>#NMOSD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12889, encryptionId=de5d1288950, topicName=NMOSD)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1f13099713, createdName=AspirantSuo, createdTime=Fri Jun 12 02:26:32 CST 2020, time=2020-06-12, status=1, ipAttribution=)]
    2020-06-12 AspirantSuo